BioTrove, Inc. and Blue Sky Biotech, Inc. have announced a collaborative effort to provide a service solution, utilizing mass spectrometry-based high-throughput screening assays on previously unscreenable drug targets.
Blue Sky will provide pharma-grade proteins that pharmaceutical companies can quickly screen against their entire small molecule libraries.
BioTrove will utilize its proprietary RapidFire™ screening technology that has screened millions of compounds.
The collaboration will initially focus on high value targets in key therapeutic areas such as metabolic disorders and oncology.
Specific examples of current projects include acyl-coenzyme A diacylglycerol acyltransferase (DGAT), 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), desaturases, and a family of histone deacetylases (HDACs).
BioTrove's RapidFire™ screening technology combines micro-fluidics and high-throughput mass spectrometry to identify lead compounds against a wide variety of challenging enzymatic targets.
High throughput assays are rapidly developed and utilize the direct detection of native, label-free substrate and product. This allows screening of a wide variety of targets, including many that are difficult or impossible to screen with conventional approaches.
"We are excited to offer the pharmaceutical community a complete HTS solution around a suite of enzymatic targets that clearly have high thereapeutic and economic value. This relationship will expand our growing list of pharmaceutical business partners," said Can ‘Jon’ Ozbal, director of RapidFire technologies at BioTrove.
"The unique combination of RapidFire™ HTS technology and Blue Sky Biotech's reagent provision expertise will provide our mutual customers with an immense competitive advantage in drug-discovery," said Paul Wengender, president of Blue Sky Biotech.